Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Shares Outstanding readings, the most recent being $100.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 0.7% to $100.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $100.1 million, a 0.7% increase, with the full-year FY2025 number at $100.1 million, up 0.7% from a year prior.
  • Shares Outstanding hit $100.1 million in Q4 2025 for Neurocrine Biosciences, roughly flat from $99.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $101.2 million in Q3 2024 to a low of $94.5 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $97.9 million (2023), compared with a mean of $97.7 million.
  • Biggest five-year swings in Shares Outstanding: grew 3.38% in 2024 and later fell 1.88% in 2025.
  • Neurocrine Biosciences' Shares Outstanding stood at $94.9 million in 2021, then increased by 1.69% to $96.5 million in 2022, then grew by 2.28% to $98.7 million in 2023, then increased by 0.71% to $99.4 million in 2024, then grew by 0.7% to $100.1 million in 2025.
  • The last three reported values for Shares Outstanding were $100.1 million (Q4 2025), $99.7 million (Q3 2025), and $99.0 million (Q2 2025) per Business Quant data.